Search Results - receptor

32 Results

Sort By:

Stable, High-Yield Production of DT390-EGF Fusion Protein for Treatment of EGF-Receptor-Positive Cancers

This invention relates to the stable and high-yield production of a high-potency toxin protein called DT390-EGF. This toxin was developed for the treatment of EGF-receptor-positive cancers, including bladder cancer. Initial methods for synthesizing DT390-EGF relied on the use of E. coli. However, the production in E. coli was difficult to prepare and...

Published: 7/25/2024 | Inventor(s): Jung-hee Woo, David Neville, Arthur Frankel, Andrew Thorburn, Michael Glode, Thomas Flaig

Keywords(s): cancers, DT390-EGF, EGF, Fusion, POSITIVE, Protein, RECEPTOR, treatment, VCXXXX, WKXXXX, XEXXXX

Category(s): TherapeuticArea > Oncology, Application > Therapeutics

Identification and Use of a Novel Functionally Selective GHSR1a Ghrelin Receptor Inhibitor, including NCGC00538279, for the Treatment of Food and Chemical Addiction

This technology includes a chemical series, including the NCGC00538279 compound, that selectively activates the GHSR1a G-protein pathway for calcium mobilization while only partially activating the beta-arrestin-2 translocation pathway. The resulting chemical series may be therapeutically valuable for addictive disorders. Activation of the GHSR1a G-protein...

Published: 7/25/2024 | Inventor(s): Noel Southall, Marc Ferrer-Alegre, Daniel Jansen, Mark Henderson, Xin Hu, David Kim, Juan Marugan

Keywords(s): ADDICTION, Chemical, FOOD, Funtionally, Ghrelin, LIGAND, NCG00538279, Novel, RECEPTOR, SELECTIVE, treatment, VEXXXX, VGXXXX, WIXXXX, WKXXXX, XEXXXX

Category(s): TherapeuticArea > Neurology, Application > Therapeutics, TherapeuticArea > Endocrinology, Application > Research Materials

Potential New Drugs for Treating or Preventing Pruritus

NIH scientists have identified new compositions that could potentially be used to treat or prevent pruritus (itchiness). The newly discovered compounds can block a newly identified itch pathway and might be effective for persistent itch caused by psoriasis, atopic dermatitis, renal failure, liver cirrhosis and chemotherapy. These compounds are different...

Published: 7/25/2024 | Inventor(s): Hans Solinski, James Inglese, Patricia Dranchak, Mark Hoon

Keywords(s): BLOCKAGE, IB6XXX, Itch, Listed LPM Vepa as of 4/15/2015, Nppb, Npr1, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, RECEPTOR, Sensation, TRANSMITTER, treatment, VOXXXX, VPXXXX, WKXXXX, XHXXXX, YAXXXX, YBXXXX, YCXXXX

Category(s): TherapeuticArea > Reproductive Health, TherapeuticArea > Oncology, Application > Consumer Products, TherapeuticArea > Infectious Disease, ResearchProducts > Research Equipment, TherapeuticArea > Ophthalmology, Application > Therapeutics, Application > Vaccines, TherapeuticArea > Endocrinology, TherapeuticArea > Dental, TherapeuticArea > Cardiology

Hybridoma Cell Line H9.2B8 Producing Monoclonal Anti-mouse CD51 (Vitronectin receptor, alpha chain) Antibody

A hybridoma cell line producing a monoclonal hamster antibody specific to mouse CD51 (vitronectin receptor, alpha chain) (clone H9.2B8) as described in J Exp Med. 1989 Jun 1;169(6):2173-90 and developed by the laboratory of Dr. Ethan Shevach at the National Institute of Allergy and Infectious Diseases.

Published: 7/25/2024 | Inventor(s): Ethan Shevach

Keywords(s): AC5XXX, Against, ALPHA, antibodies, ANTIGENS, Cell, Chain, Clone:, H9.2B8, Hamster, Hybridoma, Listed LPM Nguyen-Antczak as of 4/15/2015, Mab, Mouse, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, RECEPTOR, RM, Surface, Vitronectin, WIXXXX

Category(s): Collaboration Sought > Licensing, Application > Research Materials

Novel Dopamine D2 Receptor Antagonists and Methods of Their Use

Investigators at the NIH have identified a series of novel, small molecule antagonists of the dopamine D2 receptor. Among the dopamine receptor (DAR) subtypes, D2 DAR is arguably one of the most validated drug targets in neurology and psychiatry. For instance, all receptor-based anti-Parkinsonian drugs work via stimulating the D2 DAR, whereas all FDA...

Published: 7/25/2024 | Inventor(s): Juan Marugan, Jingbo Xiao, Marc Ferrer-Alegre, Noel Southall, R Benjamin Free, David Sibley

Keywords(s): Agents, ANTAGONISTS, ANTIPSYCHOTIC, D2, Dopamine, Human, NB2BXX, NB2XXX, Potential, RECEPTOR, SELECTIVE, VEXXXX, VNXXXX, WIXXXX, WKXXXX, YBXXXX, YCXXXX

Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Psychiatry/Mental Health, TherapeuticArea > Neurology, Application > Research Materials, Application > Therapeutics

Recombinant Sulfated HIV Envelope Protein and Methods for Making Protein

This technology comprises sulfated recombinant gp120 proteins and peptides. Also included are methods for producing sulfated recombinant gp120 proteins. The focus of this technology is on sulfation of two tyrosines in the V2 loop of the HIV major envelope glycoprotein, gp120, which increase the stability of gp120 and promote the synthesis of gp120 protein...

Published: 7/25/2024 | Inventor(s): Raffaello Cimbro, Paolo Lusso

Keywords(s): BETWEEN, CD4, DB4XXX, DBXXXX, DC5XXX, DCXXXX, DXXXXX, Envelope, gp120, HIV, INHIBIT, INTERACTION, Mimics, Peptide, Protein, RECEPTOR, That, V2-loop, VLXXXX, WIXXXX, WJXXXX, WKXXXX, YAXXXX, YBXXXX, YCXXXX, YFXXXX

Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Infectious Disease, Application > Research Materials, Application > Therapeutics, Application > Vaccines

Transgenic Mice with Constitutively Active M3 Muscarinic Receptor in Islet Beta Cells

Q490L point mutation was introduced into the rat M3 muscarinic receptor cDNA to confer persistent, constitutive (ligand-independent) activity. Expression of the M3 receptor mutant was placed under the control of a 650 bp fragment of the rat insulin promoter II (RIP II) to limit expression to the islet beta cell.

Published: 7/25/2024 | Inventor(s): Jurgen Wess

Keywords(s): Active, Beta, Cells, CONSTITUTIVELY, IDXXXX, ISLET, IXXXXX, M3, Mice, MUSCARINIC, RECEPTOR, TRANSGENIC

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, Application > Diagnostics, Application > Research Materials

Islet Beta Cell Only M3 Muscarinic Acetylcholine Receptor Knockout Mouse

Researchers at NIH have developed islet beta cell M3 muscarinic acetylcholine receptor knockout mouse. The mice were generated by crossing floxed mouse M3 muscarinic acetylcholine receptor mice with mice in which Cre recombinase was controlled by the beta-cell specific rat insulin promoter (RIP-Cre mice).

Published: 7/25/2024 | Inventor(s): Jurgen Wess

Keywords(s): ACETYLCHOLINE, Beta, Cell, IDXXXX, ISLET, IXXXXX, Knockout, M3, MUSCARINIC, RECEPTOR

Category(s): Collaboration Sought > Licensing, Application > Research Materials, Application > Diagnostics, Application > Therapeutics

Small Molecule MRS5474 with Anticonvulsant Activity for Treatment of Epilepsy

Adenosine modulates many physiological processes by activating specific adenosine receptors. These adenosine receptors play a critical role in the regulation of cellular signaling and are broadly distributed throughout the body. Thus, the ability to modulate adenosine receptor-mediated signaling is an attractive therapeutic strategy for a broad range...

Published: 7/25/2024 | Inventor(s): Dilip Tosh, Kenneth Jacobson

Keywords(s): A3, Activity, ADENOSINE, AGONISTS, Agonists:, Al, ANTAGONISTS, Anticonvulsant, Derivatives, Docking, IB1FXX, IB1XXX, IBXXXX, IXXXXX, NB1EXX, NB1HXX, NB1XXX, NBXXXX, N-Methanocarba, Nucleosides, NXXXXX, PARTIAL, Patent Category - Chemistry, POTENT, RECEPTOR, TRUNCATED

Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Neurology, Application > Diagnostics, Application > Research Materials, TherapeuticArea > Cardiology, Application > Therapeutics

Novel Small Molecule Agonists of the Relaxin Receptor as Potential Therapy for Heart Failure and Fibrosis

The present invention is directed to novel small molecule agonists of the mammalian relaxin family receptor 1 (RXFP1), including human RXFP1. Activation of RXFP1 induces: 1) vasodilation due to up-regulation of the endothelin system; 2) extracellular matrix remodeling; 3) moderation of inflammation by reducing levels of inflammatory cytokines; and...

Published: 7/25/2024 | Inventor(s): Wei Zheng, Marc Ferrer-Alegre, Catherine Chen, Alexander Agoulnik, Noel Southall, Jingbo Xiao, Juan Marugan

Keywords(s): 1, IB1XXX, IB3XXX, IB5XXX, IB6XXX, IBXXXX, IXXXXX, MODULATORS, POTENT, RECEPTOR, Relaxin, RXFP1, SELECTIVE

Category(s): Collaboration Sought > Collaboration, Application > Therapeutics, Application > Vaccines, TherapeuticArea > Cardiology, TherapeuticArea > Reproductive Health, TherapeuticArea > Immunology, Application > Research Materials, Application > Diagnostics

1 2 3 4